JP2017014255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017014255A5 JP2017014255A5 JP2016159414A JP2016159414A JP2017014255A5 JP 2017014255 A5 JP2017014255 A5 JP 2017014255A5 JP 2016159414 A JP2016159414 A JP 2016159414A JP 2016159414 A JP2016159414 A JP 2016159414A JP 2017014255 A5 JP2017014255 A5 JP 2017014255A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- complex
- nanoparticle core
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 65
- 201000011510 cancer Diseases 0.000 claims 34
- 239000002105 nanoparticle Substances 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 27
- 108091007433 antigens Proteins 0.000 claims 27
- 102000036639 antigens Human genes 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 230000000139 costimulatory effect Effects 0.000 claims 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 8
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- 102000043129 MHC class I family Human genes 0.000 claims 6
- 108091054437 MHC class I family Proteins 0.000 claims 6
- 230000000259 anti-tumor effect Effects 0.000 claims 6
- 239000000539 dimer Substances 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 5
- 239000002131 composite material Substances 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 4
- 108010075704 HLA-A Antigens Proteins 0.000 claims 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 4
- 102000043131 MHC class II family Human genes 0.000 claims 4
- 108091054438 MHC class II family Proteins 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 4
- 229910052737 gold Inorganic materials 0.000 claims 4
- 239000010931 gold Substances 0.000 claims 4
- 229910052742 iron Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- -1 4-IBBL Proteins 0.000 claims 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 2
- 108010058607 HLA-B Antigens Proteins 0.000 claims 2
- 108010052199 HLA-C Antigens Proteins 0.000 claims 2
- 108010010378 HLA-DP Antigens Proteins 0.000 claims 2
- 102000015789 HLA-DP Antigens Human genes 0.000 claims 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 claims 2
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 claims 2
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000011523 endocrine gland cancer Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 229910044991 metal oxide Inorganic materials 0.000 claims 2
- 150000004706 metal oxides Chemical class 0.000 claims 2
- 229910052976 metal sulfide Inorganic materials 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003346 selenoethers Chemical class 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 239000013638 trimer Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018381 Glomus tumour Diseases 0.000 claims 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000001597 Lynch syndrome 1 Diseases 0.000 claims 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 claims 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000002758 colorectal adenoma Diseases 0.000 claims 1
- 239000011162 core material Substances 0.000 claims 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical group C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 1
- 229960000258 corticotropin Drugs 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 210000001752 female genitalia Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000001657 hereditary nonpolyposis colorectal cancer type 2 Diseases 0.000 claims 1
- 201000001651 hereditary nonpolyposis colorectal cancer type 7 Diseases 0.000 claims 1
- 208000036427 hereditary nonpolyposis type 2 colorectal cancer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000696 magnetic material Substances 0.000 claims 1
- 239000002122 magnetic nanoparticle Chemical group 0.000 claims 1
- 210000003794 male germ cell Anatomy 0.000 claims 1
- 201000005831 male reproductive organ cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000000516 mast-cell leukemia Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000022499 mismatch repair cancer syndrome Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000009996 pancreatic endocrine effect Effects 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 208000010916 pituitary tumor Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41333010P | 2010-11-12 | 2010-11-12 | |
| US61/413,330 | 2010-11-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538208A Division JP5991979B2 (ja) | 2010-11-12 | 2011-11-11 | 癌の予防および治療のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017014255A JP2017014255A (ja) | 2017-01-19 |
| JP2017014255A5 true JP2017014255A5 (enExample) | 2017-06-08 |
Family
ID=44983530
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538208A Expired - Fee Related JP5991979B2 (ja) | 2010-11-12 | 2011-11-11 | 癌の予防および治療のための組成物および方法 |
| JP2016159414A Pending JP2017014255A (ja) | 2010-11-12 | 2016-08-16 | 癌の予防および治療のための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538208A Expired - Fee Related JP5991979B2 (ja) | 2010-11-12 | 2011-11-11 | 癌の予防および治療のための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9511151B2 (enExample) |
| EP (1) | EP2637700A2 (enExample) |
| JP (2) | JP5991979B2 (enExample) |
| KR (1) | KR20140037789A (enExample) |
| CN (2) | CN105770906A (enExample) |
| AU (2) | AU2011328077A1 (enExample) |
| BR (1) | BR112013007064A2 (enExample) |
| CA (1) | CA2817710C (enExample) |
| IL (1) | IL225471B (enExample) |
| MX (1) | MX350203B (enExample) |
| NZ (1) | NZ608695A (enExample) |
| RU (2) | RU2017119820A (enExample) |
| SG (2) | SG10201509279QA (enExample) |
| WO (1) | WO2012062904A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3269384A1 (en) * | 2007-03-07 | 2018-01-17 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of autoimmune conditions |
| US20140105980A1 (en) * | 2012-10-11 | 2014-04-17 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| EP2621523B1 (en) * | 2010-09-29 | 2017-08-09 | UTI Limited Partnership | Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres |
| US9511151B2 (en) * | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| EP2858672B1 (en) * | 2012-06-08 | 2018-04-04 | Alkermes, Inc. | Fusion polypeptides comprising mucin-domain polypeptide linkers |
| EP2711418B1 (en) * | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
| US10548957B2 (en) * | 2012-09-28 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| CA2916465C (en) | 2013-06-24 | 2023-05-23 | Neximmune | Humanized anti-cd28 antibodies and artificial antigen presenting cells |
| ES2612918T3 (es) | 2013-07-10 | 2017-05-19 | Miltenyi Biotec Gmbh | Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles |
| DK3065771T3 (da) | 2013-11-04 | 2019-06-11 | Uti Lp | Fremgangsmåder og sammensætninger til vedvarende immunterapi |
| TWI689310B (zh) | 2014-07-11 | 2020-04-01 | 巨生生醫股份有限公司 | 治療鐵缺乏症之方法 |
| CN106188237A (zh) * | 2014-09-05 | 2016-12-07 | 马恒标 | 大蒜中提取得到的抗肿瘤活性的多肽 |
| SG11201703203RA (en) | 2014-10-20 | 2017-05-30 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| KR102582035B1 (ko) | 2014-12-24 | 2023-09-22 | 넥스이뮨, 인크. | 면역요법을 위한 나노입자 조성물 및 방법 |
| KR102859521B1 (ko) | 2015-05-06 | 2025-09-12 | 유티아이 리미티드 파트너쉽 | 지속 치료를 위한 나노입자 조성물 |
| JP2018518689A (ja) * | 2015-05-14 | 2018-07-12 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | バイオマーカーとして循環腫瘍細胞を使用するがん治療の有効性をモニタリングするための方法 |
| US10481158B2 (en) | 2015-06-01 | 2019-11-19 | California Institute Of Technology | Compositions and methods for screening T cells with antigens for specific populations |
| WO2018094570A1 (zh) | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
| MX2019010171A (es) | 2017-02-27 | 2019-10-15 | Juno Therapeutics Inc | Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular. |
| WO2018165475A1 (en) | 2017-03-08 | 2018-09-13 | California Institute Of Technology | Pairing antigen specificity of a t cell with t cell receptor sequences |
| SG11201909290TA (en) | 2017-04-07 | 2019-11-28 | Uti Lp | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
| CA3067226A1 (en) * | 2017-06-16 | 2018-12-20 | Mayo Foundation For Medical Education And Research | Materials and methods for increasing immune responses |
| EP4620977A3 (en) * | 2017-07-21 | 2025-12-17 | Bruker Cellular Analysis, Inc. | Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated t cells, and uses thereof |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| EP3704230B1 (en) | 2017-11-01 | 2024-10-23 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| CA3083748A1 (en) | 2017-11-29 | 2019-06-06 | Uti Limited Partnership | Methods of treating autoimmune disease |
| CN112203680A (zh) | 2017-12-08 | 2021-01-08 | 朱诺治疗学股份有限公司 | 用于细胞疗法的表型标记和相关方法 |
| CN108359013A (zh) * | 2018-02-07 | 2018-08-03 | 上海交通大学 | 一种人工抗原递呈纳米制剂及其用于体内外扩增特异性t细胞的应用 |
| EP3853352A4 (en) * | 2018-09-21 | 2022-08-10 | Berkeley Lights, Inc. | FUNCTIONALIZED TRUCK PLATE, PROCESS FOR ITS MANUFACTURE AND ITS USE |
| CN114341175A (zh) * | 2019-05-23 | 2022-04-12 | 乌第有限合伙公司 | 包含非经典mhc的纳米颗粒及其用途 |
| US20220249389A1 (en) | 2019-07-12 | 2022-08-11 | Oregon Health & Science University | Immunotherapeutic constructs and methods of their use |
| MX2019015508A (es) | 2019-12-18 | 2021-06-21 | Univ Guadalajara | Nanopartículas para el tratamiento del cáncer. |
| IL306074A (en) | 2021-03-24 | 2023-11-01 | Alkermes Inc | UPAR antibodies and fusion proteins with them |
| CN113403276A (zh) * | 2021-06-23 | 2021-09-17 | 河北大学 | 抗体功能化的外泌体制剂及其制备方法和应用 |
| WO2024130393A1 (en) * | 2022-12-21 | 2024-06-27 | Moskovchenko Svitlana | Nanoparticle and method of synthesis thereof |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1000470A (en) | 1908-02-11 | 1911-08-15 | Frank C Widmann | Ring-mold. |
| US1017295A (en) | 1910-08-20 | 1912-02-13 | Adolph F Hensler | Journal-box. |
| US1048588A (en) | 1911-05-05 | 1912-12-31 | Adams & Westlake Co | Pole-changer. |
| US1008080A (en) | 1911-07-15 | 1911-11-07 | Jacub Schwartzman | Bed-spring. |
| US1012404A (en) | 1911-07-29 | 1911-12-19 | Frederick L S Means | Protective caster. |
| US1044155A (en) | 1912-04-11 | 1912-11-12 | Diamond Match Co | Splint-drying means for match-machines. |
| US4367110A (en) | 1979-07-02 | 1983-01-04 | Toppan Printing Co. | Decorative laminate and a manufacturing method therefor |
| US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4478946A (en) | 1981-07-02 | 1984-10-23 | South African Inventions Development Corporation | Carrier bound immunosorbent |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| EP0092227B1 (en) | 1982-04-19 | 1988-07-27 | Nissan Motor Co., Ltd. | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
| US5171582A (en) | 1985-07-31 | 1992-12-15 | Ghent William R | Treatment of iodine deficiency diseases |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5258499A (en) | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US6106840A (en) | 1988-06-23 | 2000-08-22 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| US5260422A (en) | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| US4859839A (en) | 1988-07-08 | 1989-08-22 | Counter Computer Corporation | Point-of-sale terminal for laundry or dry cleaning establishments |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| EP0630255B1 (en) | 1991-04-23 | 2002-12-18 | Anergen, Inc. | Mhc conjugates useful in ameliorating autoimmunity |
| US5200189A (en) | 1991-07-23 | 1993-04-06 | Ecolab Inc. | Peroxyacid antimicrobial composition |
| JPH07508503A (ja) | 1992-02-27 | 1995-09-21 | ザ・ボード・オブ・トラステイーズ・オブ・ザ・リランド・スタンフオード・ジユニア・ユニバーシテイ | 自己免疫性糖尿病のための初期抗原（ｅａｒｌｙ ａｎｔｉｇｅｎ） |
| JP2631436B2 (ja) | 1992-07-24 | 1997-07-16 | 徳厚 小島 | 排水立て管継手 |
| US5972336A (en) | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
| IL113139A0 (en) | 1994-03-28 | 1995-06-29 | Nycomed Imaging As | Diagnostic compositions comprising imaging agents encapsulated in liposomes |
| US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DE19508058A1 (de) | 1995-02-21 | 1996-08-22 | Schering Ag | Verfahren zur Herstellung von DTPA-Tetraestern der terminalen Carbonsäuren und deren Verwendung zur Herstellung pharmazeutischer Mittel |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| AU730457B2 (en) | 1996-08-16 | 2001-03-08 | President And Fellows Of Harvard College | Soluble monovalent and multivalent MHC class II fusion proteins, and uses therefor |
| US20050003431A1 (en) | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| CA2302779C (en) | 1997-09-16 | 2010-02-02 | Oregon Health Sciences University | Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| NZ506071A (en) | 1998-02-19 | 2003-05-30 | Harvard College | Monovalent, multivalent, and multimeric major histocompatibility complex (MHC) binding domain fusion proteins and conjugates, and uses therefore |
| JP2002513765A (ja) | 1998-05-07 | 2002-05-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫応答の調節における無視された標的組織抗原の使用 |
| DE19825371A1 (de) | 1998-06-06 | 1999-12-09 | Bayer Ag | Elektrochrome Anzeigevorrichtung mit isolierten Zuleitungen |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| US7807377B2 (en) * | 1998-10-20 | 2010-10-05 | Salvatore Albani | Method of isolating antigen-specific T cells employing artificial antigen presenting cells |
| US6150022A (en) | 1998-12-07 | 2000-11-21 | Flex Products, Inc. | Bright metal flake based pigments |
| JP2000213425A (ja) | 1999-01-20 | 2000-08-02 | Hino Motors Ltd | Ｅｇｒク―ラ |
| US7090973B1 (en) | 1999-04-09 | 2006-08-15 | Oscient Pharmaceuticals Corporation | Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics |
| AU4825700A (en) | 1999-05-06 | 2000-11-21 | Genetics Institute Inc. | Use of soluble costimulatory molecules to enhance immune responses |
| WO2001024764A2 (en) | 1999-10-06 | 2001-04-12 | The Trustees Of The University Of Pennsylvania | Cell targeting compositions and methods of using the same |
| US6585947B1 (en) | 1999-10-22 | 2003-07-01 | The Board Of Trustess Of The University Of Illinois | Method for producing silicon nanoparticles |
| US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR100379250B1 (ko) | 2000-12-04 | 2003-04-08 | 한국과학기술연구원 | 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법 |
| CA2440474A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| DE10117858A1 (de) | 2001-04-10 | 2002-10-24 | Gsf Forschungszentrum Umwelt | MHC-Tetramere |
| US20050129617A1 (en) | 2001-06-22 | 2005-06-16 | Rusung Tan | Type1 diabetes diagnostics and therapeutics |
| US20070129307A1 (en) | 2001-06-22 | 2007-06-07 | The University Of British Columbia | Insulin epitopes for the treatment of type 1 diabetes |
| US20030124149A1 (en) | 2001-07-06 | 2003-07-03 | Shalaby Shalaby W. | Bioactive absorbable microparticles as therapeutic vaccines |
| AU2002364927A1 (en) | 2001-07-10 | 2003-06-30 | North Carolina State University | Nanoparticle delivery vehicle |
| DE10144252A1 (de) | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
| AU2002367817B2 (en) | 2001-11-09 | 2008-05-29 | Nanosphere, Inc. | Bioconjugate-nanoparticle probes |
| DK1581119T3 (da) | 2001-12-17 | 2013-05-13 | Corixa Corp | Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme |
| US6688494B2 (en) | 2001-12-20 | 2004-02-10 | Cima Nanotech, Inc. | Process for the manufacture of metal nanoparticle |
| US7285289B2 (en) | 2002-04-12 | 2007-10-23 | Nagy Jon O | Nanoparticle vaccines |
| DE60334474D1 (de) | 2002-07-12 | 2010-11-18 | Univ Johns Hopkins | Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren |
| DE10310261A1 (de) | 2003-03-05 | 2004-09-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Identifizierung von Antigen-Epitopen |
| US20040197304A1 (en) | 2003-04-01 | 2004-10-07 | The Procter & Gamble Company And Alimentary Health, Ltd. | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
| US6929675B1 (en) | 2003-04-24 | 2005-08-16 | Sandia Corporation | Synthesis metal nanoparticle |
| US20050118102A1 (en) | 2003-04-28 | 2005-06-02 | Intematix Corporation | Spin resonance heating and/or imaging in medical applications |
| EP1623017B1 (en) | 2003-05-08 | 2010-09-15 | Life Technologies Corporation | Generation and isolation of antigen-specific t cells |
| CA2526425A1 (en) | 2003-05-20 | 2005-04-14 | Uti Limited Partnership | Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof |
| US7060121B2 (en) | 2003-06-25 | 2006-06-13 | Hsing Kuang Lin | Method of producing gold nanoparticle |
| WO2005007673A2 (en) | 2003-07-03 | 2005-01-27 | Rush University Medical Center | Immunogenic peptides |
| US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
| GB0321937D0 (en) | 2003-09-19 | 2003-10-22 | Univ Liverpool | Nanoparticle conjugates and method of production thereof |
| AU2004280611A1 (en) | 2003-10-09 | 2005-04-21 | Emerson Electric Co. | Valve assembly |
| DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| EP1768692B8 (en) | 2004-07-01 | 2015-06-17 | Yale University | Targeted and high density drug loaded polymeric materials |
| JP5117191B2 (ja) | 2004-10-01 | 2013-01-09 | ミダテック リミテッド | 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造 |
| WO2006054806A1 (ja) | 2004-11-22 | 2006-05-26 | Locomogene, Inc. | クローン病関連自己抗原 |
| US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| US20070059775A1 (en) | 2005-03-29 | 2007-03-15 | The Trustees Of Columbia University In The City Of New York | Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques |
| US7562421B2 (en) | 2005-04-03 | 2009-07-21 | Magen Eco Energy A.C.S. Ltd. | Connecting clasp |
| US7326399B2 (en) | 2005-04-15 | 2008-02-05 | Headwaters Technology Innovation, Llc | Titanium dioxide nanoparticles and nanoparticle suspensions and methods of making the same |
| EP1932538A4 (en) | 2005-08-25 | 2009-10-21 | Taiho Pharmaceutical Co Ltd | BIODEGRADABLE NANOPARTICLE HAVING RECYCLABLE IMMUNIZED T-EPITOPE PEPTIDE IMMOBILIZED ON OR ENCAPSULATED THEREIN |
| EP1954252B1 (en) | 2005-12-02 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Nanoparticles for use in immunogenic compositions |
| WO2007084775A2 (en) | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| ES2657504T3 (es) | 2006-08-11 | 2018-03-05 | Life Sciences Research Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| US7816814B1 (en) | 2006-08-18 | 2010-10-19 | Hennessy Michael J | Bi-directional power converters |
| WO2008083390A2 (en) | 2006-12-29 | 2008-07-10 | University Of Washington | Dual-functional nonfouling surfaces and materials |
| US8889117B2 (en) | 2007-02-15 | 2014-11-18 | Yale University | Modular nanoparticles for adaptable vaccines |
| US20150250871A1 (en) | 2007-03-07 | 2015-09-10 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| EP3269384A1 (en) | 2007-03-07 | 2018-01-17 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of autoimmune conditions |
| US20140105980A1 (en) | 2012-10-11 | 2014-04-17 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| WO2008118861A2 (en) | 2007-03-23 | 2008-10-02 | The University Of North Carolina At Chapel Hill | Discrete size and shape specific organic nanoparticles designed to elicit an immune response |
| EP3620465B1 (en) * | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| CN202189297U (zh) | 2007-07-22 | 2012-04-11 | 康代有限公司 | 用于控制电子电路的制造过程的系统 |
| JP5085240B2 (ja) | 2007-09-03 | 2012-11-28 | 日本電波工業株式会社 | 水晶デバイス及び水晶デバイスの製造方法 |
| EP2591804A3 (en) | 2007-09-24 | 2014-04-16 | Bar-Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| WO2009064273A1 (en) | 2007-11-16 | 2009-05-22 | Paul Appelbaum | Apparatus and method for packaging articles in clear plastic packages |
| EP2231181B1 (en) | 2007-12-17 | 2016-02-17 | Marfl AB | New vaccine for the treatment of mycobacterium related disorders |
| WO2009094273A2 (en) | 2008-01-15 | 2009-07-30 | Yale University | Compositions and methods for adoptive and active immunotherapy |
| AU2009211224A1 (en) | 2008-02-04 | 2009-08-13 | Ulive Enterprises Ltd | Nanoparticle conjugates |
| JP2011525477A (ja) | 2008-03-04 | 2011-09-22 | リクイディア・テクノロジーズ・インコーポレーテッド | 免疫調節剤粒子および処置方法 |
| WO2009126835A2 (en) | 2008-04-09 | 2009-10-15 | University Of Washington Techtransfer Invention Licensing | Magnetic nanoparticle and method for imaging t cells |
| US20090258355A1 (en) | 2008-04-11 | 2009-10-15 | Brookhaven Science Associates, Llc | Nanoscale Clusters and Methods of Making Same |
| CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| WO2010037397A1 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| CA2642141A1 (en) | 2008-10-20 | 2010-04-20 | Innovative Microelectronics Inc. | Flange alignment pin |
| AU2009315230A1 (en) | 2008-11-12 | 2010-05-20 | The Brigham And Women's Hospital, Inc. | Diagnosis of multiple sclerosis |
| WO2010080032A2 (en) | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
| JP2012515722A (ja) | 2009-01-20 | 2012-07-12 | ノースウェスタン ユニバーシティ | 抗原特異的寛容の誘導のための組成物および方法 |
| US8383085B2 (en) | 2009-05-29 | 2013-02-26 | University Of Manitoba | Methods of making iron-containing nanoparticles |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| GB0922066D0 (en) | 2009-12-17 | 2010-02-03 | Univ Belfast | Modulator |
| GB201003088D0 (en) | 2010-02-24 | 2010-04-14 | Univ Exeter | Method for the preparation of a novel nanoparticle conjugate |
| RU2722357C2 (ru) | 2010-07-26 | 2020-05-29 | Кью Байолоджикс Инк. | Иммуногенные противовоспалительные композиции |
| EP2640711B1 (en) | 2010-08-25 | 2015-10-14 | Davuluri, Ramamohan Rao | Improved process for the preparation of rufinamide |
| EP2611827A4 (en) | 2010-09-03 | 2014-03-19 | Univ Oregon Health & Science | RECOMBINANT T-CELL RECEPTOR LIGANDS WITH Covalently Bonded PEPTIDES |
| EP2621523B1 (en) | 2010-09-29 | 2017-08-09 | UTI Limited Partnership | Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| AU2012306243B2 (en) | 2011-09-07 | 2016-10-20 | Midatech Limited | Nanoparticle-peptide compositions |
| EP2758780A4 (en) | 2011-09-22 | 2015-09-16 | Marv Entpr Llc | METHOD OF TREATING MULTIPLE SCLEROSIS |
| EP2591801A1 (en) | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
| US20130128138A1 (en) | 2011-11-18 | 2013-05-23 | Shenzhen China Star Optoelectronics Technolog Co., LTD. | Flat Panel Display Device, Stereoscopic Display Device, Plasma Display Device |
| WO2013086500A1 (en) | 2011-12-09 | 2013-06-13 | The Johns Hopkins University | Artificial antigen presenting cells having a defined and dynamic shape |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US20150150996A1 (en) | 2012-06-06 | 2015-06-04 | Northwestern University | Compositions and methods for antigen-specific tolerance |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| SG11201504414UA (en) | 2012-12-21 | 2015-07-30 | Hoffmann La Roche | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
| US9335768B2 (en) | 2013-09-12 | 2016-05-10 | Lam Research Corporation | Cluster mass flow devices and multi-line mass flow devices incorporating the same |
| DK3065771T3 (da) | 2013-11-04 | 2019-06-11 | Uti Lp | Fremgangsmåder og sammensætninger til vedvarende immunterapi |
| AU2015279738A1 (en) | 2014-06-25 | 2016-12-22 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| CA2969056C (en) | 2014-12-19 | 2023-09-05 | Eth Zurich | Chimeric antigen receptors and methods of use |
| EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| BR112017020750A2 (pt) | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| KR102859521B1 (ko) | 2015-05-06 | 2025-09-12 | 유티아이 리미티드 파트너쉽 | 지속 치료를 위한 나노입자 조성물 |
| MA44907A (fr) | 2015-09-11 | 2018-07-18 | Agenus Inc | Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation |
| AU2017357865B2 (en) | 2016-11-09 | 2024-10-31 | Uti Limited Partnership | Recombinant pMHC class II molecules |
| SG11201909290TA (en) | 2017-04-07 | 2019-11-28 | Uti Lp | Assay to measure the potency of receptor-ligand interactions in nanomedicines |
| CA3083748A1 (en) | 2017-11-29 | 2019-06-06 | Uti Limited Partnership | Methods of treating autoimmune disease |
-
2011
- 2011-11-10 US US13/294,109 patent/US9511151B2/en active Active
- 2011-11-11 CN CN201610192518.9A patent/CN105770906A/zh active Pending
- 2011-11-11 BR BR112013007064A patent/BR112013007064A2/pt not_active Application Discontinuation
- 2011-11-11 AU AU2011328077A patent/AU2011328077A1/en not_active Abandoned
- 2011-11-11 CA CA2817710A patent/CA2817710C/en active Active
- 2011-11-11 SG SG10201509279QA patent/SG10201509279QA/en unknown
- 2011-11-11 CN CN201180054383.5A patent/CN103260648B/zh not_active Expired - Fee Related
- 2011-11-11 NZ NZ608695A patent/NZ608695A/en not_active IP Right Cessation
- 2011-11-11 WO PCT/EP2011/069931 patent/WO2012062904A2/en not_active Ceased
- 2011-11-11 EP EP11782609.9A patent/EP2637700A2/en not_active Withdrawn
- 2011-11-11 KR KR1020137009786A patent/KR20140037789A/ko not_active Ceased
- 2011-11-11 RU RU2017119820A patent/RU2017119820A/ru not_active Application Discontinuation
- 2011-11-11 SG SG2013028568A patent/SG189909A1/en unknown
- 2011-11-11 RU RU2013121571A patent/RU2623038C2/ru not_active IP Right Cessation
- 2011-11-11 JP JP2013538208A patent/JP5991979B2/ja not_active Expired - Fee Related
- 2011-11-11 MX MX2013004581A patent/MX350203B/es active IP Right Grant
-
2013
- 2013-03-24 IL IL225471A patent/IL225471B/en active IP Right Grant
-
2016
- 2016-03-08 AU AU2016201498A patent/AU2016201498B2/en not_active Ceased
- 2016-08-16 JP JP2016159414A patent/JP2017014255A/ja active Pending
- 2016-11-16 US US15/353,602 patent/US10172955B2/en active Active
-
2018
- 2018-11-26 US US16/200,199 patent/US11000596B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017014255A5 (enExample) | ||
| RU2017119820A (ru) | Композиции и способы профилактики и лечения злокачественных новообразований | |
| Liu et al. | Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory | |
| Chen et al. | Driving CARs on the uneven road of antigen heterogeneity in solid tumors | |
| Houot et al. | T-cell–based immunotherapy: adoptive cell transfer and checkpoint inhibition | |
| Schettini et al. | Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives | |
| Palumbo et al. | Systemic cancer therapy: achievements and challenges that lie ahead | |
| Zhou et al. | Aptamers: A promising chemical antibody for cancer therapy | |
| Baxevanis et al. | Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy | |
| JP2013543855A5 (enExample) | ||
| Curiel | Immunotherapy: a useful strategy to help combat multidrug resistance | |
| WO2018065623A2 (en) | Immunogenic compounds for cancer therapy | |
| JP2018536655A5 (enExample) | ||
| Kamath | Cancer vaccines: An unkept promise? | |
| Jindal et al. | Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice | |
| Lee et al. | Engineered nanocarriers for targeted lung cancer therapy: mechanistic innovations and recent clinical progress | |
| Singh et al. | Cancer immunotherapy: Moving forward with peptide T-cell vaccines | |
| Abdul Kuddus | Nanoparticles to deal with gastric cancer | |
| Rosell et al. | Future Directions in the Second-Line Treatment of Non–Small Cell Lung Cancer | |
| Emens et al. | Cancer vaccines in combination with multimodality therapy | |
| Paul et al. | Smart multifunctional nanosystem: Next-generation drug delivery platform for drug-resistant breast cancer | |
| Akbar et al. | Inorganic nanoparticulate carriers in cancer vaccination | |
| Sasada et al. | A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies | |
| Pedrazzoli et al. | Developments in Solid Tumours | |
| Mhaske et al. | Therapeutic Potential of Nanocrystals for Targeting Lymphoid Carcinoma |